NCT05938036 - Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

May 1, 2027

Study Completion Date

July 1, 2027

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Interventions

DRUG

ALT-100 mAb

Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.

DRUG

ALT-100 (Placebo)

Normal saline solution via IV solution

Trial Locations (1)

85721

Banner University of Arizona, Tucson